Overexpression of O-GlcNAc-Transferase Associates with Aggressiveness of Mass-Forming Cholangiocarcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue SUPPL.1, 2012, Pages 101-105

  Phoomak, Chatchai ^a   Silsirivanit, Atit ^a   Wongkham, Chaisiri ^a   Sripa, Banchob ^a   Puapairoj, Anucha ^a   Wongkham, Sopit ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Glycosylation; N acetylglucosaminidase; O GlcNAcylation; O linked N acetylglucosaminyl transferase

Indexed keywords

N ACETYLGLUCOSAMINE;

BILE DUCT CARCINOMA; DOWN REGULATION; GLYCOSYLATION; HUMAN; PROTEIN PROCESSING; UPREGULATION;

ACETYLGLUCOSAMINE; CHOLANGIOCARCINOMA; DOWN-REGULATION; GLYCOSYLATION; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; UP-REGULATION;

EID: 84874077524     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.KKSuppl.101     Document Type: Article

References (37)

1. Bimboese P, Gibson CJ, Schmidt S, Xiang W, Ehrlich BE (2011). Isoform-specific regulation of the inositol 1,4,5-trisphosphate receptor by O-linked glycosylation. J Biol Chem, 286, 15688-97.
2. Blechacz B, Gores GJ (2008). Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology, 48, 308-21.
3. Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM, et al (2009). Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer, 45, 33-47.
4. Butkinaree C, Park K, Hart GW (2010). O-linked beta-Nacetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta, 1800, 96-106.
5. Caldwell SA, Jackson SR, Shahriari KS, et al (2010). Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene, 29, 2831-42.
6. Comer FI, Hart GW (2000). O-Glycosylation of nuclear and cytosolic proteins. Dynamic interplay between O-GlcNAc and O-phosphate. J Biol Chem, 275, 29179-82.
7. Fromowitz FB, Viola MV, Chao S, Oravez S, Mishriki Y, et al (1987). ras p21 expression in the progression of breast cancer. Hum Pathol, 18, 1268-75.
8. Greene FL, Page DL, Flaming ID, et al (2002). Manual for Staging of Cancer. Springer-Verlag, NewYork.
9. Gu Y, Mi W, Ge Y, et al (2010). GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res, 70, 6344-51.
10. Hart GW, Housley MP, Slawson C (2007). Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature, 446, 1017-22.
11. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O (2011). Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem, 80, 825-58.
12. Higashi M, Yonezawa S, Ho JJ, et al (1999). Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology, 30, 1347-55.
13. Khan SA, Thomas HC, Toledano MB, Cox IJ, Taylor-Robinson SD (2005). p53 Mutations in human cholangiocarcinoma: a review. Liver Int, 25, 704-16.
14. Krzeslak A, Forma E, Bernaciak M, Romanowicz H, Brys M (2012). Gene expression of O-GlcNAc cycling enzymes in human breast cancers. Clin Exp Med, 12, 61-5.
15. Krzeslak A, Jozwiak P, Lipinska A (2011). Down-regulation of beta-N-acetyl-D-glucosaminidase increases Akt1 activity in thyroid anaplastic cancer cells. Oncol Rep, 26, 743-9.
16. Krzeslak A, Pomorski L, Lipinska A (2010). Elevation of nucleocytoplasmic beta-N-acetylglucosaminidase (O-GlcNAcase) activity in thyroid cancers. Int J Mol Med, 25, 643-8.
17. Krzeslak A, Wojcik-Krowiranda K, Forma E, Bienkiewicz A, Brys M (2012). Expression of genes encoding for enzymes associated with O-GlcNAcylation in endometrial carcinomas: clinicopathologic correlations. Ginekol Pol, 83, 22-6.
18. Li ZR, Wu YF, Ma CY, et al (2011). Down-regulation of c-Myc expression inhibits the invasion of bile duct carcinoma cells. Cell Biol Int, 35, 799-802.
19. Liu BQ, Meng X, Li C, et al (2011). Glucosamine induces cell death via proteasome inhibition in human ALVA41 prostate cancer cell. Exp Mol Med, 43, 487-93.
20. Lynch TP, Ferrer CM, Jackson SR, et al (2012). Critical role of O-GlcNAc transferase in prostate cancer invasion, angiogenesis and metastasis. J Biol Chem.
21. Mi W, Gu Y, Han C, et al (2011). O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta, 1812, 514-519.
22. Morise Z, Sugioka A, Tokoro T, et al (2010). Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol, 2, 58-64.
23. Nakanuma Y, Sato Y, Harada K, et al (2010). Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol, 2, 419-27.
24. O'Dell MR, Huang JL, Whitney-Miller CL, et al (2012). Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res, 72, 1557-67.
25. Ozcan S, Andrali SS, Cantrell JE (2010). Modulation of transcription factor function by O-GlcNAc modification. Biochim Biophys Acta, 1799, 353-64.
26. Pan X, Wilson M, Mirbahai L, et al (2011). In vitro metabonomic study detects increases in UDP-GlcNAc and UDP-GalNAc, as early phase markers of cisplatin treatment response in brain tumor cells. J Proteome Res, 10, 3493-500.
27. Park SY, Roh SJ, Kim YN, et al (2009). Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep, 22, 649-57.
28. Patel T (2006). Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol, 3, 33-42.
29. Qin JM, Fu XY, Li SJ, et al (2003). Gene and protein expressions of p28GANK in rat with liver regeneration. World J Gastroenterol, 9, 2523-7.
30. Sawanyawisuth K, Silsirivanit A, Kunlabut K, et al (2011). A novel carbohydrate antigen expression during development of Opisthorchis viverrini-associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis. Parasitol Int, 61, 151-4.
31. Silsirivanit A, Araki N, Wongkham C, et al (2011). A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma. Cancer, 117, 3393-403.
32. Slawson C, Hart GW (2011). O-GlcNAc signalling: implications for cancer cell biology. Nat Rev Cancer, 11, 678-84.
33. Slawson C, Housley MP, Hart GW (2006). O-GlcNAc cycling: how a single sugar post-translational modification is changing the way we think about signaling networks. J Cell Biochem, 97, 71-83.
34. Sripa B, Pairojkul C (2008). Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol, 24, 349-56.
35. Yonglitthipagon P, Pairojkul C, Chamgramol Y, Loukas A, Mulvenna J, et al (2012). Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma. Hum Pathol.
36. Zachara NE, Hart GW (2006). Cell signaling, the essential role of O-GlcNAc! Biochim Biophys Acta, 1761, 599-617.
37. Zhu Q, Zhou L, Yang Z, et al (2011). O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol.